Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Children and Adults 2024: Executive Summary
Kimia Honarmand,Michael Sirimaturos,Eliotte L Hirshberg,Nicholas G Bircher,Michael S D Agus,David L Carpenter,Claudia R Downs,Elizabeth A Farrington,Amado X Freire,Amanda Grow,Sharon Y Irving,James S Krinsley,Michael J Lanspa,Micah T Long,David Nagpal,Jean-Charles Preiser,Vijay Srinivasan,Guillermo E Umpierrez,Judith Jacobi,Eliotte L. Hirshberg,Nicholas G. Bircher,Michael S. D. Agus,David L. Carpenter,Claudia R. Downs,Elizabeth A. Farrington,Amado X. Freire,Sharon Y. Irving,James S. Krinsley,Michael J. Lanspa,Micah T. Long,Guillermo E. Umpierrez
DOI: https://doi.org/10.1097/ccm.0000000000006173
IF: 8.8
2024-03-16
Critical Care Medicine
Abstract:Hyperglycemia is common in critically ill patients, is a marker for severity of illness, and may contribute directly to morbidity or mortality. Intensive insulin therapy (INT) had been shown to influence mortality and morbidity outcomes in specific research settings with early dextrose/nutritional support, but benefits are difficult to achieve in most clinical settings without significant risk of hypoglycemia and associated complications. Current consensus guidelines suggest targeting a moderate or conventional glucose control (CONV) level of glycemia to avoid extremes and minimize glycemic variability, excessive workload, and ensure consistent utilization ( 1 , 2 ). This guideline addresses the clinical equipoise regarding target glucose levels for critically ill adult and pediatric (defined as ≥ 42 wk adjusted gestational age) patients, along with monitoring frequency and methods ( 3 ). Neonatal patients were excluded due to their fundamental differences in physiology, nutrition, and inadequate expertise within the guideline taskforce. This executive summary describes key points from the full guideline document. Further, this guideline is an update of the 2012 guidelines for insulin infusion therapy ( 4 ).
critical care medicine